 Good morning. Why don't we go ahead and get started? Welcome everyone to Lovely Silver Spring. This is the nicest time of the year to be in Washington, and I think we'll have some decent weather, so that's great. I'm Terry Minolio. I lead the Division of Genomic Medicine at NHGRI, and would just mention this is the tenth in a series of genomic medicine meetings that the people sort of sitting around me have helped to plan. We have a genomic medicine working group that is advisory to our advisory council. It's a working group actually of our advisory council, and so from Carol on to Mark, including Eric and Laura Rodriguez who will be here shortly. Yeah. Yeah, there are a few that are down for the count, but they'll be back shortly. This meeting we wanted to focus on implementation of pharmacogenomics and research to facilitate that implementation. We would emphasize that this is not a meeting to talk about more discovery of pharmacogenomic variants, even though that's important and stuff that needs to be done. It's not a meeting to talk about developing new drugs or functionalizing variants or those things. It's really to take established knowledge and implement it in care. You all received a series of papers in the mailing, the background mailings that I hope you've taken a look at. There's one quote in there that I just can't resist reading from the lady to my left here, and Bill Evans quote, our enthusiasm for advancing molecular technology and defining the human genome has not yet been matched by willingness to incorporate this technology and knowledge into well-controlled and monitored clinical trials, and I would add care for the patient. So something that we really need to keep in mind this week or four. What I'd like to do this morning before we get started is just to do introductions of everybody in the room, because one of the things we do with these meetings is to try to encourage everybody to interact and hopefully develop collaborations or sharing that of information and techniques. So with that, I think the only other announcements I need to make are that Teji Rock-Reburse at the end of the row here is taking your talks. And so if you haven't given your talks to her, please do so really soon. Remember that all of this is being videotaped, so be careful what you say. And we do post these webcasts, it's live webcast, and then we will post it as an archive, and we do get a fair number of views after the fact. The restrooms are down the hall, food is behind us, lunch will be served there. And just before lunch we'd like to gather, there's a very nice patio out here and we'd like to gather for a photo of the group, and our colleague Ernesto will be taking pictures, live action shots as it were as we go through. Teji has some very handy but annoying little signs that will tell the speakers. There's one, five, two, and one minute. So please do try to stick to time so that we maintain discussion time. So with that, as I said, I'm Terry Manolio. I lead the Division of Genomic Medicine at the National Human Genome Research Institute. Mary Relling, chair of the Pharmaceutical Department at St. Jude Children's Research Hospital in Memphis. Simone Wolpe in HGRI. I'm a program director in the Division of Genomic Medicine with Terry Manolio. Dan Rodin at Vanderbilt and a member of this advisory group. Howard McLeod at Moffitt Cancer Center. Dan and I are not sharing a seat. We're just sitting really close together. I'm on Howard's lap. Pat Deverka, principal researcher at the American Institutes for Research and a member of this committee as well. Hi, I'm Carol Bolt from the Jackson Lab and I'm also on the Genomic Medicine Working Group. Heidi Rehm from Harvard Medical School and the Broad Institute and a PI of ClinGen. Hi, I'm Marilyn Ritchie. I'm director of Biomedical and Translational Informatics at Geisinger Health System. Hi, I'm Laura Rasmussen-Torbeck. I'm in the Preventive Medicine Department at Northwestern University. Steve Leder, the division of Clinical Pharmacology, Toxicology and Therapeutic Innovation at Children's Mercy Hospital in Kansas City. Laurie Cavallari, I'm associate director of the Personalized Medicine Program at University of Florida. Kristen Weitzel, also an associate director of the Personalized Medicine Program at the University of Florida. Hi, I'm Julie Johnson. I'm director of the Personalized Medicine Program at UF and also PI of one of the Ignite projects funded that's focused in pharmacogenomics. Peter O'Donnell at the University of Chicago and I'm the associate director of our Center for Personalized Therapeutics. Uli Burcal from the Medical College of Wisconsin and I'm working with Mary on rallying on her Peach In For Kids project which we've been doing pre-emphasic genotyping for a long time. Teji Rokroboros, Dick University. Melpikasapium, a program analyst in the division of Genomic Medicine at NSGRI. Good morning, my name is John Wilson. I'm the chief medical information officer at a company called Optum which is the services division of the United Health Group. I'm leading the genomics effort at Optum. Dick Winschelbaum from the Mayo Clinic and I lead our Pharmacogenomics program in the Center for Individualized Medicine. Manoli Parare, the department of pharmacology at Northwestern and I'm the PI for Account which is one of the precision medicine center grants. I'm Todd Score from Indiana University, the division of clinical pharmacology and I'm one of the PIs of our, one of the Ignite network sites. I'm Josh Denning from Vanderbilt. Medicine Informatics and like Todd also serves one of the PIs of an Ignite project. Hi, I'm Lynn Dressler. I'm from Mission Health System in Asheville, North Carolina, a community health system and I'm director of the personalized medicine program there. I'm Paul Anderson, father of Angela who died of toxic epidermal necrolysis. Mark Williams, director of the Genomic Medicine Institute, Geisinger Health System, member of the working group. Rex Chisholm, Northwestern University in Chicago, also member of the working group and PI of one of the emerged clinical sites. Jeff Ginsberg from Duke University where I direct the Center for Applied Genomics and Precision Medicine. Also a PI of an Ignite project that has nothing to do with pharmacogenetics. Eric Green, director of NHGRI. Which way are we going? I pointed that way. Oh, you pointed that way. I'm sorry. Sheena Faraday, I'm a science writer at NHGRI. Donna Messersmith, I'm with the Genomic Healthcare Branch, NHGRI. Bob Wilden, chief of the Genomic Healthcare Branch at NHGRI. Ben Spahnem, senior advisor to Dr. Green on genomics and health disparities. Rebecca, policy office at NHGRI. Hi, I'm sorry. Jeff Scruing from the Division of Genomic Medicine at NHGRI. Onepin Anderson, the mother of Angela Anderson. She died from the tinge back in December 28th, 2015. Mike Mikalkiewicz, research scientist for our healthcare. I'm part of Ignite program with Evander Bilt. We are introducing pharmacogenomics to community healthcare system. Murray Brilliant, Marshfield Clinic Research Institute. I direct our Center for Human Genetics and Personalized Medicine Research Project. Jyothi Dayal, program officer, Division of Genomic Medicine at NHGRI. Sylvia Garvey, Division of Genomic Medicine at NHGRI. Josiah Allen, director of medical affairs at 1M, a pharmacogenomics company. Hi, Jenna Baker from NIDDK, and I manage a program called Illuminating the Drugable Genome. Great, thank you all very much. So I'd like to introduce one of my two co-chairs, Simona being the other. Mary Relling, who will make some opening remarks.